Literature DB >> 35391579

[Role of innate receptors in chronic inflammation and autoimmunity].

Marina Babic1,2, Chiara Romagnani3,4.   

Abstract

Elucidating the basis of chronic disease courses and the development of appropriate treatment methods for inflammatory diseases still represent a big challenge for medical science, as the mechanisms driving aberrant immune reactions are mostly still unknown. Of particular interest is the identification of checkpoints that regulate the function and differentiation of proinflammatory cells during the pathogenesis, along with methods for modulation of specific checkpoints as a treatment approach. Innate receptors, such as members of the natural killer group 2 family (NKG2X), natural cytotoxicity receptors (NCR) or Toll-like receptors (TLRs), play an important role in modulating the immune response. NKG2 member D (NKG2D) is a potent activating receptor of the immune system, known as a sentinel for cellular danger signals presented by cells exposed to endoplasmic reticulum (ER) stress, cell death or an inflammatory cytokine milieu. NKG2A/C bind the non-classical HLA class I molecule, sense changes in ligand expression associated with malignant transformation and cellular stress and their main function is to send inhibitory or activating signals to NK cells and subsets of T cells. In this review, we present our latest knowledge on the understanding of the role of innate receptors in the context of chronic inflammation and autoimmunity with special emphasis on danger sensor receptors NKG2D and NKG2A/C.
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Immune response; Innate immunity; Innate lymphoid cells; Natural killer group 2 family; Rheumatoid arthritis

Mesh:

Substances:

Year:  2022        PMID: 35391579     DOI: 10.1007/s00393-022-01185-6

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.530


  27 in total

Review 1.  NKG2D Receptor and Its Ligands in Host Defense.

Authors:  Lewis L Lanier
Journal:  Cancer Immunol Res       Date:  2015-06       Impact factor: 11.151

Review 2.  Resetting the immune system with immunoablation and autologous haematopoietic stem cell transplantation in autoimmune diseases.

Authors:  Tobias Alexander; Renate Arnold; Falk Hiepe; Andreas Radbruch
Journal:  Clin Exp Rheumatol       Date:  2016-07-20       Impact factor: 4.473

3.  A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.

Authors:  Gerd R Burmester; Iain B McInnes; Joel Kremer; Pedro Miranda; Mariusz Korkosz; Jiri Vencovsky; Andrea Rubbert-Roth; Eduardo Mysler; Matthew A Sleeman; Alex Godwood; Dominic Sinibaldi; Xiang Guo; Wendy I White; Bing Wang; Chi-Yuan Wu; Patricia C Ryan; David Close; Michael E Weinblatt
Journal:  Ann Rheum Dis       Date:  2017-02-17       Impact factor: 19.103

4.  RORγt⁺ innate lymphoid cells acquire a proinflammatory program upon engagement of the activating receptor NKp44.

Authors:  Timor Glatzer; Monica Killig; Johannes Meisig; Isabelle Ommert; Merlin Luetke-Eversloh; Marina Babic; Daniela Paclik; Nils Blüthgen; Rainer Seidl; Claudia Seifarth; Jörn Gröne; Minoo Lenarz; Katharina Stölzel; Dominik Fugmann; Angel Porgador; Anja Hauser; Alexander Karlas; Chiara Romagnani
Journal:  Immunity       Date:  2013-06-20       Impact factor: 31.745

Review 5.  Immunological memory in rheumatic inflammation - a roadblock to tolerance induction.

Authors:  Patrick Maschmeyer; Hyun-Dong Chang; Qingyu Cheng; Mir-Farzin Mashreghi; Falk Hiepe; Tobias Alexander; Andreas Radbruch
Journal:  Nat Rev Rheumatol       Date:  2021-04-06       Impact factor: 20.543

6.  Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells.

Authors:  Quirin Hammer; Timo Rückert; Eva Maria Borst; Josefine Dunst; André Haubner; Pawel Durek; Frederik Heinrich; Gilles Gasparoni; Marina Babic; Adriana Tomic; Gabriella Pietra; Mikalai Nienen; Igor Wolfgang Blau; Jörg Hofmann; Il-Kang Na; Immo Prinz; Christian Koenecke; Philipp Hemmati; Nina Babel; Renate Arnold; Jörn Walter; Kevin Thurley; Mir-Farzin Mashreghi; Martin Messerle; Chiara Romagnani
Journal:  Nat Immunol       Date:  2018-04-09       Impact factor: 25.606

7.  Fate mapping of IL-17-producing T cells in inflammatory responses.

Authors:  Keiji Hirota; João H Duarte; Marc Veldhoen; Eve Hornsby; Ying Li; Daniel J Cua; Helena Ahlfors; Christoph Wilhelm; Mauro Tolaini; Ursula Menzel; Anna Garefalaki; Alexandre J Potocnik; Brigitta Stockinger
Journal:  Nat Immunol       Date:  2011-01-30       Impact factor: 25.606

8.  NK cell receptor NKG2D enforces proinflammatory features and pathogenicity of Th1 and Th17 cells.

Authors:  Marina Babic; Christoforos Dimitropoulos; Quirin Hammer; Christina Stehle; Frederik Heinrich; Assel Sarsenbayeva; Almut Eisele; Pawel Durek; Mir-Farzin Mashreghi; Berislav Lisnic; Jacques Van Snick; Max Löhning; Simon Fillatreau; David R Withers; Nicola Gagliani; Samuel Huber; Richard A Flavell; Bojan Polic; Chiara Romagnani
Journal:  J Exp Med       Date:  2020-08-03       Impact factor: 14.307

9.  Autoimmune Th17 Cells Induced Synovial Stromal and Innate Lymphoid Cell Secretion of the Cytokine GM-CSF to Initiate and Augment Autoimmune Arthritis.

Authors:  Keiji Hirota; Motomu Hashimoto; Yoshinaga Ito; Mayumi Matsuura; Hiromu Ito; Masao Tanaka; Hitomi Watanabe; Gen Kondoh; Atsushi Tanaka; Keiko Yasuda; Manfred Kopf; Alexandre J Potocnik; Brigitta Stockinger; Noriko Sakaguchi; Shimon Sakaguchi
Journal:  Immunity       Date:  2018-05-22       Impact factor: 31.745

10.  Correction: NK cell-derived GM-CSF potentiates inflammatory arthritis and is negatively regulated by CIS.

Authors:  Cynthia Louis; Fernando Souza-Fonseca-Guimaraes; Yuyan Yang; Damian D'Silva; Tobias Kratina; Laura Dagley; Soroor Hediyeh-Zadeh; Jai Rautela; Seth Lucian Masters; Melissa J Davis; Jeffrey J Babon; Bogoljub Ciric; Eric Vivier; Warren S Alexander; Nicholas D Huntington; Ian P Wicks
Journal:  J Exp Med       Date:  2020-05-04       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.